CRISPR Therapeutics (pending) $CRSP scaled down its IPO to 4 million common shares from 4.7 million and lowered the price to $14, down from the original range of $15-17. Underwriters will have an option to purchase an additional 600k shares. The closing date is October 24. Trading commences today.
The company was co-founded by one of the CRISPR/Cas9 discoverers, Emmanuelle Charpentier. The technology is labelled as the next big thing in biotech. Therefore the stock will be on investors’ radar along with Editas Medicine $EDIT and Intellia Therapeutics $NTLA.